| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/11/2001 | CA2373945A1 Remedies for drug-resistant hypercalcemia |
| 01/11/2001 | CA2373753A1 Preserving a hemoglobin blood substitute with a transparent overwrap |
| 01/11/2001 | CA2373735A1 Fviia antagonists |
| 01/11/2001 | CA2373352A1 Adenoviral vectors for treating disease |
| 01/11/2001 | CA2372935A1 Novel antifungal agents and fungicides, method for the production thereof and their use |
| 01/10/2001 | EP1067194A1 Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof |
| 01/10/2001 | EP1067190A1 Gene therapy for enhancing and/or inducing angiogenesis |
| 01/10/2001 | EP1067183A1 Novel g protein-coupled receptor proteins |
| 01/10/2001 | EP1067141A1 A male-specific protein homologue involved in histocompatibility |
| 01/10/2001 | EP1067140A1 Novel hemolytic active proteins and genes encoding the same |
| 01/10/2001 | EP1067139A1 Cyclophilin identified as an allergen |
| 01/10/2001 | EP1067138A1 Hydroxyproline derivatives |
| 01/10/2001 | EP1067136A1 New peptide derivatives |
| 01/10/2001 | EP1066834A2 Pharmaceutical compositions comprising a phagocyte-modulating agent |
| 01/10/2001 | EP1066830A2 Uses and compositions for treating primary and secondary tumors of the central nervous system (cns) |
| 01/10/2001 | EP1066526A1 Pf-4 receptor assay |
| 01/10/2001 | EP1066398A1 Gpi-122, a novel glycophosphatidylinositol-anchored protein |
| 01/10/2001 | EP1066382A1 Lens epithelial cell derived growth factor |
| 01/10/2001 | EP1066380A2 Soluble t cell receptor |
| 01/10/2001 | EP1066379A1 Protein variant of the net1 locus |
| 01/10/2001 | EP1066378A2 Lyst protein complexes and lyst interacting proteins |
| 01/10/2001 | EP1066377A1 Methods for prevention and treatment of cancer |
| 01/10/2001 | EP1066370A1 Stimulated monocyte derived cells, their preparation and uses |
| 01/10/2001 | EP1066327A2 Expression of fusion proteins |
| 01/10/2001 | EP1066325A1 G-protein fusion receptors and chimeric gaba b? receptors |
| 01/10/2001 | EP1066323A1 Treatment and prevention of vascular disease |
| 01/10/2001 | EP1066321A2 Formulation having a papilloma virus-specific protein, and the production and use thereof |
| 01/10/2001 | EP1066320A1 Orphan nuclear receptor |
| 01/10/2001 | EP1066319A1 Production methods and uses of a retrovirus |
| 01/10/2001 | EP1066316A1 Cinnamic acid derivatives having cell adhesion modulating activity |
| 01/10/2001 | EP1066315A1 Use of inhibitors of mammalian asparaginyl endopeptidase for therapy of autoimmune disease |
| 01/10/2001 | EP1066310A1 Neokine protein and nucleic acid molecules and uses therefor |
| 01/10/2001 | EP1066285A1 Antagonists of gonadotropin releasing hormone |
| 01/10/2001 | EP1066061A1 Use of scatter factor to enhance angiogenesis |
| 01/10/2001 | EP1066060A2 Mesenchymal stem cells as immunosuppressants |
| 01/10/2001 | EP1066059A1 Formulations for protection of peg-interferon alpha conjugates |
| 01/10/2001 | EP1066057A1 Hemoglobin-polysaccharide conjugates |
| 01/10/2001 | EP1066054A2 Use of active p40 conjugates for nasal delivery |
| 01/10/2001 | EP1066051A1 Sciellin and uses thereof |
| 01/10/2001 | EP1066050A2 Application of hsp70 proteins |
| 01/10/2001 | EP1066049A1 Pharmaceutical compositions for prolonged peptide release and preparation method |
| 01/10/2001 | EP1066048A1 A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof |
| 01/10/2001 | EP1066047A1 Methods and materials for treating inflammatory diseases |
| 01/10/2001 | EP1066045A1 Mammalian-derived peptides for the treatment of microbial infection |
| 01/10/2001 | EP1066043A2 Materials and methods relating to the treatment of conditions involving mast cells, basophils and eosinophils |
| 01/10/2001 | EP1066041A1 THE USE OF ESTRADIOL DERIVATIVES FOR TREATING SIDE-EFFECTS DURING AND/OR AFTER GnRHa THERAPY |
| 01/10/2001 | EP1056722A4 Bisulfate salt of hiv protease inhibitor |
| 01/10/2001 | EP0896525A4 Methods of dry powder inhalation |
| 01/10/2001 | EP0742791B1 Macrocyclic difluorostatone derivatives useful as antiviral agents |
| 01/10/2001 | EP0725797B1 Bivalent thrombin inhibitors |
| 01/10/2001 | EP0701607B1 Preparation and use of transgenic mice lacking expression of cd28 |
| 01/10/2001 | CN1279716A Human gene Hsg 3 |
| 01/10/2001 | CN1279690A Soluble single-chain T-cell receptor proteins |
| 01/10/2001 | CN1279689A Vitamin D receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof |
| 01/10/2001 | CN1279615A Combination of hypertensin converting enzyme inhibitor with a diuretic for treating microcirculation disorders |
| 01/10/2001 | CN1279614A Antistress agents and functional foods |
| 01/10/2001 | CN1279606A Use of inhibitors of the renin-angiotensin system for the treatment of hypoxia or impaired metabolic function |
| 01/10/2001 | CN1279288A Recombination human epidermal growth factor gene, its expression product and its application |
| 01/10/2001 | CN1279236A Salt as thrombin inhibitor |
| 01/10/2001 | CN1279111A Nutritive bioenzyme liquor for sobering up and its preparing process |
| 01/10/2001 | CN1279110A In-colon release-controlled thymopeptide capsule and process for extracting and separating thymopeptide |
| 01/10/2001 | CN1279109A Tonic oral liquid of sheep placenta extract |
| 01/10/2001 | CN1279068A Aqueous solution for parenteral absorption |
| 01/10/2001 | CN1279036A Method and composition for extending sevice life of intestinal canal |
| 01/10/2001 | CN1060521C Method for gene clone of inhibitory factor for hyperplasia of inner blood vessel cells in human body's real tumor, and using same to anti tumer blood vessel regeneration |
| 01/10/2001 | CN1060366C Luteotropic preparation for parturient women |
| 01/09/2001 | US6172278 Ikaros transgenic cells and mice |
| 01/09/2001 | US6172219 Esterification, lactonization, salt formation; cosmetics, food packaging, drug carriers |
| 01/09/2001 | US6172216 Oligonucleotide sequences which are used for the treatment of autoimmune diseases, cancer, amplified and reduced apoptosis, hyperplasia and viral diseases; anticarcinogenic agents |
| 01/09/2001 | US6172212 Pea3 is a tumor suppressor |
| 01/09/2001 | US6172211 Nucleotide sequences which codes a protein that modulates tumor propagation; for the treatment of cancer; antitumor agents; anticarcinogenic agents; antiproliferative agents |
| 01/09/2001 | US6172210 Nucleotide sequences which code enzymatic protein associated with phosphatides; for reduction and prevention of fibrin coagulation and vascular thrombosis; for diagnosing coagulation defects |
| 01/09/2001 | US6172203 Method for extracting and purifying pulmonary surfactant |
| 01/09/2001 | US6172202 Synthesis of polymer bio-active conjugates |
| 01/09/2001 | US6172201 Cellular receptor for HIV-1 Vpr essential for G2/M phase |
| 01/09/2001 | US6172195 Polypeptide associated with the modulation of signal transduction; for the diagnosis and treatment of defects in signal transduction |
| 01/09/2001 | US6172194 ARF-p19, a novel regulator of the mammalian cell cycle |
| 01/09/2001 | US6172192 Polypeptide or peptide associated microorganism infection; for diagnosis and prevention protozoan infection of mammals |
| 01/09/2001 | US6172191 Protein for inhibition and activation of protooncogene Ras and method for isolation thereof |
| 01/09/2001 | US6172190 Enzymatic polypeptide associated with apoptosis; for treatment of defects in apoptosis; for detection of modulators of apoptosis |
| 01/09/2001 | US6172187 Mammalian polypeptide associated with immune response; for the modulation of apoptosis |
| 01/09/2001 | US6172185 Antimicrobial cationic peptide derivatives of bactenecin |
| 01/09/2001 | US6172116 Use of aminoadamantane compounds as immunoregulators |
| 01/09/2001 | US6172107 Mycophenolate salt disintegrates selectively in intestines |
| 01/09/2001 | US6172101 Treating human immunodeficiency virus infections |
| 01/09/2001 | US6172098 Methods and compositions for increasing the anaerobic working in tissues |
| 01/09/2001 | US6172096 Administering 4-pyrazolylbenzenesulfonamide derivatives to treat autoimmune diseases |
| 01/09/2001 | US6172088 Administering gonadotropin releasing hormone inhibitor |
| 01/09/2001 | US6172086 Methods and compositions for stimulating neurite growth |
| 01/09/2001 | US6172082 α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
| 01/09/2001 | US6172080 6-azaindole compounds as antagonists of gonadotropin releasing hormone |
| 01/09/2001 | US6172068 Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| 01/09/2001 | US6172060 Therapy for sexual disorders |
| 01/09/2001 | US6172048 Composition containing nucleic acids, preparation and uses |
| 01/09/2001 | US6172047 Therapy for nervous system tumors |
| 01/09/2001 | US6172046 Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
| 01/09/2001 | US6172044 Acylated enol derivative of α-ketoesters and α-ketoamides |
| 01/09/2001 | US6172043 Treatments for neurotoxicity in Alzheimer's disease caused by β amyloid peptides |
| 01/09/2001 | US6172042 Synthetic peptides that inhibit IL-6 activity |
| 01/09/2001 | US6172041 Nervous system disorders |